In patients with chemotherapy-pretreated KRAS-mutant NSCLC, the response rates and progression-free survival were enhanced by the inclusion of Sbruumetinib, as shown in a phase II trial. This evidence concerns the gene KRAS and non-small cell lung carcinoma.